Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

EDITOR:
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.

CE PLANNERS:
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships.

Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.

INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:

Arnel Pallera, MD, Panel Member, has disclosed that he has no relevant financial relationships.

Jessica K. Altman, MD, Panel Member, has disclosed that she is a scientific advisor for Astellas Pharma US, Inc, Bristol-Myers Squibb Company, Fujifilm Corporation, Janssen Pharmaceutica Products, LP, and Syros Pharmaceuticals.

Ellin Berman, MD, Panel Member, has disclosed that she has no relevant financial relationships.

Michael Deininger, MD, PhD, Panel Vice-Chair, has disclosed that he receives consulting fees and/or honoraria from ARIAD Pharmaceuticals, Inc., Incyte Corporation, Novartis Pharmaceuticals Corporation, and Pfizer Inc.; is a scientific advisor for ARIAD Pharmaceuticals, Inc., Cell Therapeutics, Inc., Incyte Corporation, Novartis Pharmaceuticals Corporation, and Pfizer Inc.; receives grant/research support from Bristol-Myers Squibb Company, Gilead Sciences, Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc.

Jerald P. Radich, MD, Panel Chair, has disclosed that he is a scientific advisor for ARIAD Pharmaceuticals, Inc., Incyte Corporation, and Novartis Pharmaceuticals
Corporation; and receives grant/ research support and consulting fees and/or honoraria from Novartis Pharmaceuticals Corporation.

Hema Sundar, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.